SOSUA BAY, Dominican Republic, May 11, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced today that following its success in attaining exclusive rights for RNL Bio Company Ltd's licenses, technology and equipment which allows PLBI's wholly owned subsidiary, RegenoBody, S.A. to treat anyone within the Caribbean, Central and/or South America, that the laboratory needed to perform the work is being designed by RNL Bio for shipment to the RegenoBody facility in the Dominican Republic. The laboratory will be designed according to the specifications required of RNL Bio in Korea so that it can duplicate the success of RNL Bio in regenerating human stem cells.
The initial concept of bringing what was once stereotyped as a controversial treatment to this hemisphere was based upon more than a year of research and the actual treatment and successful results of PLBI's President, Armando Casciati. After Mr. Casciati's treatment, he acquired the majority control of PLBI.pk, in an effort to accelerate the process of bringing stem cell technology to the Western Hemisphere.
Mr. Casciati stated, "Entrepreneurs typically look merely for profit opportunities. I am proud to have found such an incredible life opportunity which will help serve the public with some of the latest technological advances in medical history. I believe our alliance with RNL Bio Company will prove to be a life changing opportunity for our clients, as it has been for me."
RNL Bio Company LTD is considered a leader in stem cell technology with a wealth of treatments. After years of investment and research, RNL has developed technology ranging from cosmetic and arthritic needs to spinal cord injury and cancer treatments.
Korean FDA approved RNL's human clinical study to treat patients with spinal cord injury using 'RNL-Astrostem' that is based on fat derived adult stem cells.
In early 2009, RNL Bio publicly presented its three years' preclinical trial results showing a perfect safety profile and remarkable efficacy potential. RNL was approved by the Korean government to begin phase I human trial using these adult stem cells and we believe it is the world's first trial to treat spinal cord injury with adult stem cells derived from a patients' own fat tissue.
Since the Korean FDA approval, RNL Bio has progressively increased the utility of its RNL-Astrostem technology. RNL-Astrostem is administered by intravenous infusion so patients don't have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of RNL Bio, said, "Our stem cell therapeutics involves no immune rejection because the stem cells are exactly the patient's own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed the safest therapeutics to help devastated patients with incurable diseases."
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:
RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc. brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists, in conjunction with RNL Bio, have been regarded as the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.
FORWARD-LOOKING STATEMENT:
This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the Company undertakes no obligation to update such statements.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment